| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:HDAC6-IN-4
CAS:2709103-20-6
Package:25mg/RMB 10600;100mg/RMB 17500;50mg/RMB 13800
|
Heptanamide, 7-[[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]amino]-N-hydroxy- manufacturers
- HDAC6-IN-4
-
- $1520.00 / 25mg
-
2025-10-27
- CAS:2709103-20-6
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Heptanamide, 7-[[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]amino]-N-hydroxy- Basic information |
| | Heptanamide, 7-[[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]amino]-N-hydroxy- Chemical Properties |
| density | 1.131±0.06 g/cm3(Predicted) | | pka | 9.48±0.20(Predicted) |
| | Heptanamide, 7-[[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]amino]-N-hydroxy- Usage And Synthesis |
| Uses | HDAC6-IN-4 (C10) is a potent, orally active and highly selective HDAC6 inhibitor with an IC50 value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity[1]. | | in vivo | HDAC6-IN-4 (C10) (0-100 mg/kg; i.g.; once daily for 21 days) shows excellent antitumor activity and significantly promoted T cell response in a dose-dependent manner, with no obvious toxicity[1]. | Animal Model: | Five-week-old C57BL/6 mice (immune-related CT26 xenograft model)[1]. | | Dosage: | 50 and 100 mg/kg | | Administration: | Oral gavage, once daily for 21 days | | Result: | Resulted in a substantial tumor growth and tumor tissue size inhibition in a dose-dependent way. Showed significantly high antitumor activity (TGI = 75%) at 100 mg/kg. Raised the plasma IFN-g level and the numbers of CD+ and CD3+CD+ (activated cytotoxic T) cells. Decreased CD4+CD25+CD127low/- T regulatory cells. Showed no obvious toxicity. |
| | IC 50 | HDAC6: 23 nM (IC50); HDAC3: 46 nM (IC50); HDAC2: 172 nM (IC50); HDAC8: 2175 nM (IC50); HDAC1: 3604 nM (IC50) | | References | [1] Xi Xu, et al. Novel biphenyl-based scaffold as potent and selective histone deacetylase 6 (HDAC6) inhibitors: Identification, development and pharmacological evaluation. Eur J Med Chem. 2022 Apr 5;233:114228. DOI:10.1016/j.ejmech.2022.114228 |
| | Heptanamide, 7-[[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]amino]-N-hydroxy- Preparation Products And Raw materials |
|